1. Basic Information
Diseases Protected Against
- Diphtheria: Toxin-mediated bacterial infection (Corynebacterium diphtheriae) causing a pseudomembrane in the throat and airway obstruction; toxin can cause myocarditis and peripheral neuropathy. Case-fatality ~5–10%, higher in young children. Rare in the U.S. due to vaccination (~0–5 cases/year).
- Tetanus (Lockjaw): Toxin-mediated infection (Clostridium tetani) from wound contamination. Causes painful muscle rigidity and spasms; can cause respiratory failure. Case-fatality ~10–20%. Universal; not contagious, so herd immunity does not apply. ~30 cases/year in U.S.; nearly all in unvaccinated or under-vaccinated persons.
- Pertussis (Whooping Cough): Bacterial respiratory infection (Bordetella pertussis) causing paroxysmal cough, post-tussive emesis, and apnea in infants. Highest mortality in infants <3 months. Cyclical outbreaks every 3–5 years. The switch from whole-cell (DTwP) to acellular (DTaP) vaccine in the 1990s reduced reactogenicity but may have resulted in less durable immunity.
CDC Recommended Schedule (United States, 2025)
| Dose/Age | Product | Notes |
|---|---|---|
| 2 months | DTaP | Minimum age 6 weeks |
| 4 months | DTaP | |
| 6 months | DTaP | |
| 15–18 months | DTaP | 4th dose; minimum 6 months after dose 3 |
| 4–6 years | DTaP | 5th dose; not needed if 4th dose given at ≥4 years |
| 11–12 years | Tdap | Single booster; can be given at ≥7 years |
| Pregnancy (27–36 weeks) | Tdap | Every pregnancy, regardless of prior Tdap history; primarily to protect newborn from pertussis via maternal antibody transfer |
| Every 10 years (adults) | Td or Tdap | Decennial booster; one Tdap replaces one Td booster |
Source: CDC ACIP, 2025 Child & Adolescent and Adult Immunization Schedules.
Licensed Products (U.S.)
- Daptacel® (Sanofi) — DTaP for infants/children. Licensed 2002.
- Infanrix® (GSK) — DTaP for infants/children. Licensed 1997.
- Adacel® (Sanofi) — Tdap for ages 10–64. Licensed 2005. Reduced diphtheria toxoid and pertussis antigen content compared to DTaP.
- Boostrix® (GSK) — Tdap for ages ≥10. Licensed 2005.
- Combination vaccines: Kinrix (DTaP-IPV), Quadracel (DTaP-IPV), Pediarix (DTaP-HepB-IPV), VAXELIS (DTaP-IPV-Hib-HepB), Pentacel (DTaP-IPV-Hib). Combination vaccines use the same DTaP components.
2. Pre-Licensure Clinical Trial Data
Historical Context: DTwP to DTaP Transition
Whole-cell pertussis (DTwP) vaccines were introduced in the 1940s and were highly effective but reactogenic—commonly causing high fever, prolonged crying, and febrile seizures. Safety concerns (including a hypothesized association with encephalopathy, later not confirmed) led to the development of acellular pertussis (DTaP) vaccines, licensed in the U.S. between 1991 (first DTaP) and 2002 (Daptacel). The U.S. switched from DTwP to DTaP for all doses by 2002.
DTaP Pre-Licensure Trials (Daptacel / Infanrix)
The pivotal DTaP trials enrolled several thousand infants each. Daptacel (trial P3T06) included ~4,983 infants who received Daptacel vs. ~1,651 who received DTwP. Infanrix trials were multinational and similarly sized.
| Metric | DTaP Data | Evidence Strength |
|---|---|---|
| Combined DTaP safety database (pre-licensure) | ~10,000+ infants across all products | Moderate |
| Efficacy (pertussis, DTaP) | ~80–85% (clinical pertussis definition) in initial trials; waning immunity documented post-licensure | Strong |
| Safety follow-up duration | Generally 30 days post-dose for SAEs; limited long-term follow-up | Limited |
Tdap Pre-Licensure Trials (Adacel / Boostrix, 2005)
Adacel was evaluated in ~4,500 adolescents/adults. Boostrix in ~4,100. Both compared to Td (tetanus-diphtheria) vaccine. Primary endpoint was immunogenicity non-inferiority to the adult Td with demonstration of pertussis antibody responses.
Most Common Adverse Reactions
| Reaction | DTaP (infants) | Tdap (adolescents/adults) |
|---|---|---|
| Injection site pain | ~25–40% | ~60–75% |
| Injection site swelling | ~15–25% | ~20–30% |
| Fever ≥38°C | ~15–30% (lower than DTwP ~40–60%) | ~3–8% |
| Irritability/fussiness | ~30–55% | N/A |
| Drowsiness/decreased activity | ~30–45% | N/A |
| Headache | N/A | ~20–30% |
| Fatigue | N/A | ~20–30% |
Sources: Respective prescribing information; FDA review documents. Rates vary by study, product, and dose number.
Key Limitations
- No placebo control: Modern DTaP trials used DTwP or other DTaP products as comparators, not placebo. This is ethically appropriate but limits the ability to detect absolute adverse event rates attributable to vaccination.
- Waning immunity: Pre-licensure trials demonstrated initial efficacy but were not designed to assess durability. Post-licensure data have revealed substantially shorter duration of protection from acellular pertussis vaccines compared to whole-cell vaccines.
- Combination vaccine complexity: Safety signals in combination vaccines (DTaP-IPV-Hib-HepB) are difficult to attribute to individual antigens.
- Tdap in pregnancy: Initial licensure did not include safety data in pregnancy; the recommendation for every-pregnancy Tdap is supported by post-licensure observational data, not pre-licensure RCTs.
3. Post-Licensure Safety Data
Vaccine Safety Datalink (VSD)
The VSD has conducted extensive surveillance on DTaP/Tdap vaccines. Key findings:
- Febrile seizures: DTaP is associated with a small increased risk of febrile seizures in the 0–1 day window post-vaccination in infants, particularly with concomitant PCV and influenza vaccines. Risk is ~1 per 15,000–25,000 doses.
- Extensive limb swelling (ELS): With DTaP, ELS (involving ≥2/3 of the upper arm) is reported in ~2–6% of children after the 4th and 5th booster doses. Self-limited; not a contraindication to subsequent doses.
- Tdap in pregnancy: Multiple VSD studies have found no increased risk of adverse pregnancy outcomes (preterm birth, low birth weight, congenital anomalies) or maternal adverse events associated with Tdap during pregnancy. A VSD study (Kharbanda et al., 2014; N>29,000 pregnancies) found no association with adverse birth outcomes.
- Guillain-Barré Syndrome (GBS): No consistent signal with DTaP. For Tdap, VSD rapid cycle analysis found no significantly elevated GBS risk, though tetanus toxoid-containing vaccines have been hypothesized to have a very small association in some studies (see Section 4).
VAERS
| VAERS Metric (DTaP/Tdap, cumulative) | Approximate Figures |
|---|---|
| Total DTaP doses distributed (estimated) | >1 billion doses globally since the 1990s |
| Most commonly reported AEs | Injection site reactions, fever, irritability (infants); injection site pain, headache, fatigue (Tdap in adolescents/adults) |
| Notable signal | Hypotonic-hyporesponsive episodes (HHE) in infants—resolved and well-characterized as rare, self-limited events associated primarily with DTwP; far less common with DTaP (~1–2 per 100,000 doses) |
⚠ Critical Caveat
VAERS data represent unverified reports temporally associated with vaccination. A report to VAERS does not mean the vaccine caused the event. VAERS cannot be used to calculate incidence rates or establish causality.
Major Independent Reviews
| Review | Year | Key Findings |
|---|---|---|
| IOM — "Adverse Effects of Vaccines" | 2012 | Favors acceptance of causal relationship for anaphylaxis and shoulder injury related to vaccine administration (SIRVA). Favors rejection for type 1 diabetes, autism, and SIDS. Evidence inadequate for GBS and chronic urticaria. |
| IOM — "DTaP and SIDS" | 2003 | Rejects causal association between DTaP and SIDS. Multiple large studies consistently find no association. |
| NASEM — Vaccine Safety Review | 2020 | No evidence the recommended schedule (including DTaP/Tdap) is associated with adverse neurodevelopmental outcomes. |
4. Documented Adverse Events — Evidence of Association
▶ Strong Evidence of Causal Association
- Injection site reactions (pain, swelling, erythema): Very common. Extensive limb swelling (2–6%) with booster doses—self-limited. Strong
- Fever (infants): ~15–30% with DTaP; lower than DTwP (40–60%). Strong
- Febrile seizures: Small increased risk in the 0–1 day post-vaccination window (~1 per 15,000–25,000 doses), particularly with concomitant vaccines. Strong
- Crying/inconsolability (infants): Common (10–30%). Self-limited (1–2 days). Strong
- Hypotonic-hyporesponsive episode (HHE): Rare (~1–2 per 100,000 DTaP doses). Self-limited; does not cause long-term sequelae. Strong
- Anaphylaxis: ~1–3 per million doses. Attributable to vaccine components. Strong
- Shoulder Injury Related to Vaccine Administration (SIRVA): Bursitis/tendonitis from improper injection technique (too high on the deltoid). Not antigen-specific; procedure-related. Strong
▶ Moderate or Preliminary Evidence
- Guillain-Barré Syndrome (GBS): IOM deemed evidence inadequate. Some tetanus toxoid studies suggest a possible very small increase, not consistently replicated. VSD rapid cycle analysis has not found a significant signal. Limited
▶ Published Evidence Does Not Support a Causal Association
- SIDS: Multiple large studies; no association. IOM (2003) rejected causality. No Association
- Autism: No association. IOM (2012) rejected causality. No Association
- Encephalopathy: Thought to be associated with DTwP in rare cases; large studies of DTaP have not found an association. IOM (2012) favored rejection for DTaP and encephalopathy. No Association
- Adverse pregnancy outcomes (Tdap): Multiple VSD and registry studies; no increased risk. No Association
5. Disease Prevention Benefits
Pre-Vaccine vs. Post-Vaccine Era (United States)
| Metric | Pre-Vaccine Era | Post-Vaccine Era |
|---|---|---|
| Diphtheria cases (annual) | ~200,000 (1920s); ~15,000 deaths/year | <5 cases/year since 2000; last U.S. death 2003 |
| Tetanus cases (annual) | ~500–600 (1940s) | ~30/year; nearly all unvaccinated |
| Pertussis cases (annual) | ~200,000 (pre-1940s) | ~10,000–50,000 (post-DTaP era, with cyclical peaks); resurgence in the 2010s attributed to waning DTaP immunity |
| Pertussis infant mortality | ~5,000–7,000 deaths/year | ~10–20 deaths/year (primarily infants <3 months too young for vaccination; maternal Tdap has reduced this further) |
Source: CDC Pink Book; MMWR surveillance summaries.
Key Observations
- Diphtheria and tetanus: Near-elimination in the U.S., demonstrating high and durable vaccine effectiveness.
- Pertussis resurgence: The switch from DTwP to DTaP reduced reactogenicity but may have reduced durability of protection. A 2012 Washington State epidemic (~5,000 cases) and a 2014 California epidemic (~11,000 cases) occurred in highly vaccinated populations, documenting waning DTaP immunity. Adolescent Tdap boosters and maternal Tdap are strategies to address this.
- Maternal Tdap effectiveness: Maternal Tdap during pregnancy has been shown to prevent ~78–91% of pertussis cases in infants <2 months of age (the highest-risk population), according to multiple observational studies (Amirthalingam et al., UK, 2014; Skoff et al., U.S., 2017).
6. Evidence Summary
Overall Assessment
DTP vaccines have been in use for >70 years. The safety profile of the current DTaP/Tdap products is well-characterized for common adverse events and extensively studied for rare outcomes. The primary evidence gap is the durability of pertussis protection, which post-licensure data have shown to be shorter than initially expected. Injection site and fever-related reactions are common but self-limited. Serious adverse events (anaphylaxis, febrile seizures, HHE) are rare and well-characterized.
| Domain | Evidence Grade | Key Finding |
|---|---|---|
| Diphtheria/tetanus effectiveness | Strong | Near-elimination; durable immunity |
| Pertussis effectiveness (initial) | Strong | ~80–85% effective first 1–2 years |
| Pertussis durability (waning) | Strong | Significant waning by 3–5 years post-vaccination |
| Maternal Tdap for infant protection | Strong | ~78–91% effective in preventing infant pertussis |
| Febrile seizures | Strong | ~1 per 15,000–25,000 doses; well-characterized |
| GBS | Limited | Inadequate data; no consistent signal |
| SIDS | No Association | Multiple large studies; no association |
7. Key References
- IOM. Adverse Effects of Vaccines: Evidence and Causality. National Academies Press; 2012. nationalacademies.org
- CDC. Epidemiology and Prevention of Vaccine-Preventable Diseases (Pink Book) — Diphtheria, Tetanus, Pertussis chapters. cdc.gov/pinkbook
- Kharbanda EO, et al. Safety of Tdap vaccine in pregnant women. JAMA. 2014;312(18):1897–1904. DOI: 10.1001/jama.2014.14825
- Skoff TH, et al. Impact of the US maternal Tdap vaccination program. Clin Infect Dis. 2017;65(12):1977–1983.
- Amirthalingam G, et al. Effectiveness of maternal pertussis vaccination in England. The Lancet. 2014;384(9953):1521–1528.
- CDC. Vaccine Safety Datalink (VSD). cdc.gov/vaccine-safety/about/vsd.html
- CDC/FDA. VAERS. vaers.hhs.gov
- CDC. 2025 Child & Adolescent Immunization Schedule. cdc.gov/vaccines/hcp/imz-schedules